title: Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?
abstract: A recent prospective clinical trial provides further evidence that breast cancers arising in germline BRCA1 mutation carriers are highly sensitive to cisplatin chemotherapy. The potential significance of these data for the management of patients with BRCA1-related and BRCA2-related breast cancer is discussed.
authors.forename: Nicholas C
authors.initials: NC
authors.lastname: Turner
authors.forename: Andrew N J
authors.initials: AN
authors.lastname: Tutt
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D002945:Cisplatin / Q000627:therapeutic use*; D005260:Female; D019398:Genes, BRCA1; D006801:Humans
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin